Return to map

Testing a Novel Drug for Inhibiting Oral Cancer in Cats , 2013

Principal investigator: Dr. Stuart C. Helfand, Oregon State University



Feline oral squamous cell carcinoma is a devastating and painful cancer. There are few available treatments, and there is no cure. Affected cats usually do not live more than six months. Researchers will investigate a novel therapeutic approach incorporating dasatinib, a small-molecule tyrosine kinase inhibitor, into treatment. Dasatinib has shown promise in treating oral squamous cell carcinoma in humans, and this research focuses on the drug’s potential as a novel therapy for treating this disease in cats.


Evaluating Drugs to Treat Hemangiosarcoma, 2009-2010

Principal investigator: Dr. Stuart C. Helfand, Oregon State University



Hemangiosarcoma remains one of the deadliest canine cancers. Despite treatments such as chemotherapy, immunotherapy and surgery, dogs rarely live beyond six months after diagnosis. New approaches are needed to improve the survival time of dogs afflicted with this devastating disease. This study will expand on the research team's previous research into a novel class of drugs called tyrosine kinase inhibitors that may have the potential to control the growth of hemangiosarcoma. The results will help to clarify abnormalities that contribute to hemangiosarcoma proliferation and may ultimately lead to new treatment options for this aggressive cancer.